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 7 1 Introduction 
1 Introduction 
 
The immune system is a powerful means against a broad spectrum of 
infectious agents in the environment, such as viruses, bacteria, fungi and prions. 
Successful elimination is guaranteed by two fractions which can interact intensely: 
On the one hand, the innate immune system provides granulocytes and 
macrophages that follow physiological barriers such as skin and mucous 
membrane. On the other hand, delayed but specific immune response is 
maintained by the adaptive immune system (Dempsey et al., 2003). Immune cells 
from both sections originate from hematopoietic stem cells in the bone marrow. A 
central capacity of the immune system is that it can distinguish between self and 
non-self-antigens (Jiang et al., 2009). In case of transplantation, a fully competent 
immune system recognizes foreign antigens on transplant tissue and in 
consequence, leads to rejection of the transplant. To avoid rejection of transplant 
tissue, suppression of the host immune system has to be maintained. 
 
1.1 The Adaptive Immune System 
 
The adaptive immune system differs from the innate immune system by its 
specific and delayed immune response. The adaptive or acquired immune system 
is also capable of memorizing experienced infections which lead to a fast and 
efficient elimination of invasive pathogens. Cellular components of this very 
specific immune response are antigen presenting cells (APCs), T cells and B- cells. 
Lymphocytes develop from hematopoietic stem cells and expose antigen specific 
receptors which recognize peptides and proteins. During maturation of 
lymphocytes somatic recombination of antigen specific receptors enables a highly 
specific B cell and T cell receptor repertoire. Theoretically, 1014 different B cell 
receptors (BCR) and 1018 different T cell receptors (TCR) are available (Lehrer, 
2004). In general, two types of immune responses can be differentiated: the B cell 
derived humoral immune response and the T cell mediated cellular immune 
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response. Here in this study we focused on T cell mediated immune response and 
their interaction with foreign antigens. 
 
1.1.1 Antigen Recognition by T Cells 
 
T cells develop from common lymphoid progenitors (CLP) in the bone 
marrow and mature in the thymus. The TCR is a transmembrane protein, 
composed of two chains, the alpha and beta chains, which are associated with the 
CD3 complex (Borst et al., 1996; Call et al., 2005). Recognition of foreign antigens is 
only possible when peptides are exposed on the surface of the body’s own cells.  
Foreign antigens can originate from viruses or intracellular bacteria which are 
processed intracellularly and then exposed on the surface; similarly for other 
pathogens or their fragments which are processed after endocytosis. T cells 
identify infected cells only if foreign peptides are presented on host specific 
glycoproteins which are defined as major histocompatibility complex (MHC) 
molecules.  Discovery of highly polymorphic genes located in the MHC explained 
the powerful immune response to transplanted tissue (Murphy, K.P. (2012): 
Janeway’s Immunobiology. 8th Ed. New York).  
 
1.1.2 Major Histocompatibility Complex (MHC) 
 
Characteristic for T cell recognition of antigens is the TCR which interacts 
with MHC surface molecules. MHC molecules are expressed on lymphoid and non-
lymphoid tissue except on erythrocytes.  There are two types of MHC: MHC class I 
and MHC class II. Their function is to present foreign antigens on the cell surface to 
T cells so that viral and / or bacterial replication in cells can be stopped by cell 
killing. Peptides derived from the cytosol are transported to the endoplasmic 
reticulum where they fuse with newly synthesized MHC class I molecules. This 
complex is exposed on the cell surface of APCs which present foreign antigens to 
CD8+ T cells. Peptides generated by degradation of proteins in intracellular 
endosomal vesicles combine with MHC class II molecules. CD4+ T cells then 
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recognize the complex of peptide and MHC class II molecules on the cell surface of 
APCs. CD8+ T cells recognize antigen in the context of MHC class I molecules 
whereas CD4+ T cells recognize antigen in the context of MHC class II, a process 
which is called MHC-restriction. CD4+ and CD8+ T cells recognize foreign antigen 
on self-MHC molecules (self MHC-restricted) or self or foreign antigen on foreign-
MHC molecules (allo MHC-restricted). Genetically, MHC molecules are encoded on 
chromosome 6 in humans and on chromosome 17 in mice and are highly 
polymorphic which makes it difficult for viruses and bacteria to evade the immune 
response ("Complete sequence and gene map of a human major histocompatibility 
complex. The MHC sequencing consortium," 1999).  
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Genetic organization of the major histocompatibility complex in human and in mouse. 
(Murphy, K.P. (2012): Janeway’s Immunobiology. 8th Ed. New York. Chapter 6) 
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1.1.3 Cytokines 
 
Cytokines are key molecules which enable cells to communicate and to 
interact via cytokine secretion. Cytokines are small proteins that have specific 
impact on target cells. Cytokines vary in their names depending on their origins. 
Lymphokines, are cytokines made by lymphocytes, monokines come from 
monocytes, chemokines are named due to their chemotactic activity and 
interleukins are cytokines which are made by leucocytes and serve as cell 
interacting molecules between leucocytes (Moreno Brea et al., 2009). Regulation of 
suppressive or activating effects in target cells is maintained by pro-inflammatory 
and anti-inflammatory cytokines. In this study, interferon-γ played a crucial role as 
pro-inflammatory and interleukin-10 as inhibitory immunosuppressive cytokine.  
 
1.1.3.1 Interferon-γ (IFN-γ) 
 
IFN-γ is one of the different types of interferon besides IFN-α and IFN-β. 
IFN-γ is also known as type-II interferon, whereas IFN-α and IFN-β belong to type-I 
interferon. It activates innate immune responses and mediates anti-viral effects. 
During viral infection, the main sources of IFN-γ production are CD8+ and CD4+ T 
cells. Signal transduction undergoes the Jak-Stat pathway. IFN-γ mediates 
activation of macrophages and granulocytes for phagocytosis and cell proliferation 
(Schroder et al., 2004). 
 
1.1.3.2 Interleukin-10 (IL-10) 
 
IL-10 is an immunoregulatory cytokine that is associated with T cell 
exhaustion. Its function during viral infection is described to be 
immunosuppressive and anti-inflammatory by suppressing cytokine production 
and proliferation of CD8+ and CD4+ T cells, leading to viral persistence.  It inhibits 
NF-κB activation through ill-defined mechanisms. A variety of cells can produce IL-
10 such as T cells, B cells and APCs (Blackburn et al., 2007; Moore et al., 2001). 
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1.2 Lymphocytic Choriomeningitis Virus (LCMV) 
 
LCMV has become an indispensable model in immunology. Due to viral 
infection experiments in mice, it was possible to start to understand T cell 
response and MHC-restriction (Zinkernagel et al., 1979, 1997).  
 
1.2.1 Virus Biology 
 
LCMV is an arenavirus, which is a non-cytopathic virus. Regarding the 
genome, LCMV contains a single stranded RNA. Its physiological reservoir is the 
house mouse and hamster (Childs et al., 1992). The first arenavirus, LCMV, has 
been isolated by Charles Armstrong in 1933. During an epidemic study in St. Louis, 
the virus has been detected. As common house mice provide an LCMV reservoir, 
human beings can be in contact with the virus. In our days, contamination with 
LCMV in the population is approximately 5%.  Infection with LCMV in humans can 
be asymptomatic but can also provoke meningitis. In immunosuppressed patients 
such as transplanted recipients, donor derived LCMV infection in solid organ 
transplantation (SOT) leads to higher morbidity and mortality. Vertical 
transmission of LCMV in pregnancy is not well studied but first approach assumes 
complications and higher morbidity for the fetus. 
To get insight into mechanism in viral clearance, different strains of virus 
exist (Ahmed et al., 1988; Zinkernagel et al., 1986). Concerning the immune 
response, we distinguish between strains inducing a chronic and an acute 
infection. Strains as Armstrong and WE enable an acute infection in mice, the virus 
can be cleared 8 days post-infection. Armstrong is a neurotropic LCMV strain 
whereas WE is a visceral strain. Chronic infections are well described for Clone 13 
and docile. Looking closer at the infection with strain WE of LCMV, CD8+ T cell 
response can be well characterized. Great achievements in immunological 
understanding of T cell response during viral infection has been done with LCMV. 
In this study, acute infection in transplantation medicine was the focus. Therefore, 
LCMV-WE has been used for acute infection in mice.   
 12 1 Introduction 
1.2.2 Immunopathology 
 
LCMV infection is a very good model to study and understand 
immunopathology. During viral infection, antigen specific CD8+ T cells kill infected 
cells. During acute infection with LCMV strain WE high dose (2x106 PFU), T cell 
mediated tissue damage in liver takes place. Virus can be cleared but at the same 
time viral infected cells get eliminated. In consequence, tissue damage marker for 
liver are elevated. Liver enzymes such as alanine transferase (ALT) and bilirubin 
are elevated. Lactate dehydrogenase (LDH), an unspecific cell damage marker, is 
massively increased. Chronic infection with LCMV can lead to constant activation 
of T cells which consequently lead to massive immunopathology and death. In this 
study, virus titer was determined in organs to look for viral persistence and ALT 
and LDH were measured in sera (K. S. Lang, Recher, Navarini, et al., 2005; P. A. 
Lang et al., 2010). 
 
1.2.3 T Cell Exhaustion 
 
T cell exhaustion is defined as a loss of effector function (Wherry, 2011; Yi 
et al., 2010). Gradual loss can be distinguished in stages which are determined by 
diminished or vanished production of effector cytokines such as IFN-γ, increased 
expression of inhibitory receptors and deletion of antigen-specific T cells. 
Furthermore T cell exhaustion correlates with viral persistence (Wherry et al., 
2007). 
 
Figure 1.2 T cell exhaustion and immunopathology (P. A. Lang et al., 2010) 
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1.3 Tolerance in Transplantation Medicine 
  
Immune tolerance is defined as a state of specific immunological 
unresponsiveness in the immunocompetent host (Dong et al., 1999). 
Transplantation medicine has improved in the last decades and since the use of 
new immunosuppressive drugs. Still, long-term survival and chronic rejection 
remain major challenges in transplantation medicine. Moreover, 
immunosuppressive drugs bring along many side effects such as toxicity, 
malignancies and cardiovascular disease (Mihatsch et al., 1998). Therefore, 
understanding tolerance mechanism in transplantation medicine is crucial.  
 
1.3.1 Bone Marrow Transplantation (BMT)  
 
Hematopoietic stem cell transplantation (HST) is an important therapy for 
patients with acute myeloid leukemia, myelodysplastic syndrome, refractory 
relapsed lymphoma and very severe aplastic anemia. HST is the transplantation of 
multipotent hematopoietic stem cells from bone marrow, peripheral blood, or 
umbilical cord blood. It can be autologous (patients’ own stem cells) or allogenic 
(donor stem cells). Allogenic stem cell transplantation requires that the transplant 
carries compatible transplantation antigens which are determined by the 
variability of three or more loci of the MHC complex. In humans, these MHC class I 
and class II loci are named human leucocyte antigens (HLA) class I and class II. 
Once HLA testing is assessed, compatible donors are selected for HST. 
Compatibility is verified by the two major categories of HLA type (type I and type 
II). The risk that the transplanted “new” immune system attacks the recipient 
tissue increases with every HLA-mismatch and causes severe illness. This 
phenomenon is called graft versus host disease (GvHD). The risk of GvHD increases 
with mismatches of HLA Type-I genes.  Still, fully HLA-matched donor and 
recipients as in the case of syngeneic HST (siblings) can lead to GvHD.  
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1.3.2 Solid Organ Transplantation (SOT) 
 
Due to the discovery of HLA in 1967 (Turner, 2004), transplantation 
medicine progressed enormously. Solid organ transplantation means 
transplantation of organs and tissues from deceased or living donors. Organs that 
can be transplanted are the heart, kidney, liver, pancreas, intestine and thymus. 
Considering tissue transplantation, skin, heart valves, cornea, bones and tendons 
can be transplanted. Autografts are autologous transplantation within the same 
person e.g. skin-transplantation. In case of allograft transplantation, certain 
conditions have to be fulfilled. First of all, as HLA mismatch correlates with 
allograft rejection, HLA matching between donor and recipient has to be 
determined. This is assessed by serologic or DNA typing methods.  
Furthermore, detection of alloreactive T cells opposed to recipient is 
measured in mixed lymphocyte reaction (MLR). Histoincompatibility can be 
verified in vitro. If HLA match is determined by DNA typing but MLR reveals 
histoincompatibility, the donor is not compatible for the recipient. As results 
usually take a long time to be ready and organ availability is short, HLA match is 
subordinated to organ demand. Immunosuppression then supports allograft 
survival by suppressing the immune response nonspecifically. Similar to 
alloreactive T cells, alloreactive antibodies can be identified in donor-recipient 
serologic cross matching. This analysis is particularly important for vascularized 
organs such as kidney and heart. Presence of such antibodies induce hyperacute 
rejection (Kissmeyer-Nielsen et al., 1966). 
 
1.3.2.1 Heart Transplantation (HTX) 
 
Heart transplantation is the therapy of choice for patients with heart 
insufficiency. So far, limited amount of available donor organs and the rejection of 
hearts after transplantation are major problems in heart transplantation. The first 
heart transplantation was performed in South Africa in 1967. Over the last two 
decades, selection methods for donor and recipients have increasingly improved. 
In addition, introduction of immunosuppressive drugs such as cyclosporine 
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opened up new opportunities in transplantation medicine. Overall, after 
transplantation, survival in the first year is more than 90% and in the second year 
approximately 70%. The field of heart transplantation is constantly progressing. 
Advances in organ preservation, immune monitoring and immunosuppressive 
regimens are likely to lead to a better outcome and to advances in the quality and 
the length of life of heart transplant recipients (Hoffman, 2005; Hunt et al., 2008). 
 
1.4 Challenges in Transplantation Medicine 
 
In the last 20 years, transplantation medicine has strongly improved thanks 
to immunosuppressive drugs, better surgical techniques and controlling infectious 
disease. Still, lethal problems exist in transplantation medicine and tolerance 
mechanisms are not understood yet. 
 
1.4.1 Graft versus Host Disease (GvHD) 
 
Still limitation to successful bone marrow transplantation (BMT) comes 
from severe GvHD, which occurs in up to 40% - 60% of cases (Jacobsohn et al., 
2007; Jagasia et al., 2012) and leads to 15% of deaths after HST. GvHD is clinically 
grouped in an acute and chronic GvHD defined by the time of GvHD onset after HST 
with a cutoff of 100 days. Mechanistically chronic GvHD (cGvHD) usually involves 
several factors including B cell activation, production of autoantibodies and 
absence of T-regulatory cells (Treg) (Schroeder et al., 2011).  
Acute GvHD (aGvHD) is characterized by the reaction of CD8+ T cells which 
are activated by antigens presented on host MHC class I molecules (Ferrara et al., 
1991). Therefore, T cell depletion of the transplant prior BM transfer is performed 
in cases of HLA mismatch or unrelated donors and significantly reduces aGvHD 
(Ho et al., 2001; Kroger et al., 2002; Remberger et al., 2001). Due to the high 
number of registered bone marrow donors most of BMT are done in complete MHC 
class I match. Nevertheless, around 40% of patients develop aGvHD despite 
complete HLA-matching (Ferrara et al., 2009) and T cell depletion (Champlin et al., 
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2000). Preparative regimens are critical in terms of treatment of the primary 
disease and as prevention of graft rejection. Common conditioning regimens are 
either myeloablative or non-myeloablative defined by the pancytopenia caused. 
During the last 20 years, an alternative preparative regimen has been developed. 
This therapy is called reduced intensity conditioning (RIC) and causes less tissue 
damage and is associated with less GvHD (Mielcarek et al., 2003). RIC as an 
intermediate category of regimens is commonly used for elderly people to improve 
the non-relapse mortality by reducing toxicity of treatment by either whole body 
irradiation or chemotherapy (Abdul Wahid et al., 2014; Mohty et al., 2010).  
 
1.4.2 Graft Rejection 
 
Allograft rejection is a major complication in solid organ transplantation. It 
is defined as a destructive immune response against foreign tissue or organ which 
can be mediated via cellular or humoral immune response. Three categories of 
allograft rejection can be distinguished according to their mechanism and time of 
occurrence conferring to guidelines of the international society of heart and lung 
transplantation (Task Force 2: Immunosuppression and Rejection). Hyperacute 
allograft rejection happens within minutes or hours after transplantation. It is 
mediated via preformed antibodies hostile to HLA type I molecules expressed on 
endothelium. It leads to immediate loss of an allograft. 
Further, acute cellular rejection occurs within 6 months in case of HTX. As 
the name itself explains, mainly T cells are responsible for infiltration into the 
allograft. APCs of immunocompetent host migrate from foreign donor organ to 
lymphoid tissue and prime T cells. This in consequence leads to direct 
allorecognition. Recipients’ APCs are also capable to present peptide of allograft to 
T cells by indirect allorecognition (Davis et al., 2004).  
Chronic allograft rejection limits long-term survival of transplant recipients. 
Beyond the 2nd year after HTX, cardiac graft recipients suffer from cardiac allograft 
vasculopathy (CAV) in 30% of cases. Chronic rejection is multifactorial. Viral 
infection or reactivation such as cytomegalovirus (CMV) can cause chronic 
rejection. Graft rejection can be well determined by biopsy. Heart specific tissue 
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damage markers such as creatinine kinase-MB (CK-MB) and troponine I (Top I) 
can give a hint (Dengler et al., 1998). Treatment is very often too late and has to be 
optimized.  
 
1.4.3 Role of Viral Infection 
 
The main reason for graft rejection is viral infection during heart 
transplantation. 40% of the heart rejections in humans are associated with 
infections (Jung et al., 2011; Yusen et al., 2014). Those infections are mainly caused 
by herpes viruses. Considering viral infection in transplantation, we distinguish 
between reactivation of latent infections in donor organs or recipients and 
unexpected transmission of viral infections through organ transplantation which is 
defined as donor-derived viral infection. Even though, transmission of acute or 
latent infection to organ transplant recipients occurs only in about 0.2% of 
transplantation. Once it occurs, it leads to significantly increased morbidity and 
mortality in the recipients (Grossi et al., 2009). In transplantation medicine, 
expected viral infections detected by serologic analysis are known for CMV, 
hepatitis B virus (HBV) and Epstein-Barr-virus (Razonable, 2011). Special 
prophylaxis and infection management is preserved in this setting. Of greater 
concern are the unexpected viral infections transmitted via donor organs. Several 
reports of infectious diseases through SOT are published and estimated number of 
unreported cases has to be considered. Donor-derived viral infections include a 
growing number of pathogens such as HBV, herpes viruses, human T- cell 
lymphotrophic viruses (HTLV) 1 and 2, West Nile virus, Rabies, LCMV, 
polyomavirus, parvovirus B19 and many other viruses. In most of such 
transmissions the mortality is high (Ison et al., 2011; Srinivasan et al., 2005; 
Winston et al., 2014). Detection of infectious disease in donor organs is limited by 
technical means and by the short time period between death of donor and the use 
of transplant. So, routinely evaluation of donors for infectious disease is 
determined by antibody detection. Nevertheless, a time window of false negative 
detection for infectious disease exists. For example, for hepatitis C virus (HCV) the 
window from infection to seroconversion is 30-70 days. Improvements have been 
 18 1 Introduction 
done by nucleic acid testing (NAT), so that the window could be reduced. But still, 
some infections remain undetected (Fishman, 2007; Fishman et al., 2009). 
 
1.5 Aims 
 
Transplantation medicine is one of the most challenging fields in medicine.  
Mechanisms establishing tolerance towards graft and host respectively in an 
immunocompetent environment has not been understood yet. Factors influencing 
tolerance can be on the one hand minor antigen mismatches despite full HLA-
matched donor and recipient. Another problem is viral infection during BMT and 
SOT which emerged being life-threatening complications. In this study reported 
here, LCMV was a very good model to analyze differences of immune responses 
towards minor antigen and virus replication during murine bone marrow and 
heterotopic heart transplantation. The aim of this study was to investigate the 
interaction between LCMV specific CD8+ T cells and presentation of LCMV peptide 
or virus. We hypothesized that only presence of replicating virus can break 
immunological tolerance.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and Reagents 
 
Chemicals were obtained from AppliChem (Darmstadt), Merck (Darmstadt), Roth 
(Karlsruhe) or Sigma-Aldrich (Munich). 
 
Carboxyfluorescein Succinimidyl Ester (CFSE) Invitrogen, Darmstadt 
Fluorescence Activating Cell Sorter (FACS) BD Bioscience, Heidelberg 
Lysing Solution BD Bioscience, Heidelberg 
Fetal Calf Serum (FCS) Biochrom AG, Berlin 
Isofluran Delta Select GmbH, Pfullingen 
Lipopolysaccharides of Escherichia coli (LPS) Sigma, Munich 
TriFast®TRIzol  PeqLab, Erlangen 
 
Mouse IL-10 ELISA Ready-SET-Go!®  eBioscience 
 
QuantiTect Reverse Transcription Kit QIAGEN, Hilden 
SYBR®Green  (AppliedBiosystems, Darmstadt) 
 
2.1.2 Media and Solution   
 
Dulbecco’s Modified Eagle’s Medium (DMEM) PAN Biotech GmBH, Aldenbach 
 
DPBS w/o Mg2+, Ca2+  PAN Biotech GmBH, Aldenbach 
 
Phosphate Buffered Saline (PBS) DPBS, ddH2O 
 
FACS‐Buffer  PBS 
2% (v/v) FCS 
0.1% (v/v) NaN3 
2 mM EDTA 
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Erythrocyte‐Lysis‐Buffer  0.5 M NH4Cl2  
10mM KHCO3 
0.1mM EDTA 
pH 7.42 
 
EDTA‐Solution  0.5 M EDTA 
pH 8.0 
 
Iscove’s Modified Dulbecco’s Medium (IMDM) 175 ml dH2O, 50 ml 9xIMDM, 2-4 
ml 2M NaHO, sterile filtration, 
5% (v/v) FCS, 2% (w/v) PSG 
 
Overlay (Plaque Assay) 50% (v/v) IMDM Solution 
 50% (v/v) 2% Methylcellu-lose 
   
 
2.1.3 Primer 
qPCR-WEGPforw (LCMV-GP) CGA GCA TCA AAG CTG TGT ACA AT 
qPCR-WEGPrev (LCMV-GP) AAA AGG AAG CTG ACC AGT GCT AA 
GAPDH Mm_Gapdh_3_SG QuantiTect Primer 
Assay (200), Quiagen GmbH, Hilden 
 
2.1.4 Equipment  
ELISA Reader AnthosLabtecInstruments 
GmbH, Wals‐Siezenheim  
FACSCalibur BD Bioscience, Heidelberg 
Fluoreszenz‐Mikroskop HS BZ‐9000 Keyence GmbH, Neu‐Isenburg 
Kryostat CM 3050S Leica, Wetzler 
NanoDrop ND‐1000 Peqlab Biotechnologie GmbH, 
Erlangen 
TissueLyserII QIAGEN, Hilden 
Micro 220R‐Centrifuge  Andreas Hettich GmbH, 
Tuttlingen 
 
 21 2 Materials and Methods 
2.1.5 Software 
FacsDiva v&6.2.1  BD Bioscience 
FlowJo 7.6.1  TreeStar Inc., Ashland (OR, USA) 
GraphPad Prism5 GraphPad Software, La Jolla (CA, 
USA) 
MicrosoftOffice 2007  MicrosoftCorporation, Redmont 
(WA, USA) 
       
2.1.6 Antibody 
 
In this study, antibodies were directly coupled with fluorescence. 
Antibodies were obtained from BD Pharmigen (Heidelberg) and eBioscience 
(Frankfurt). Flourochromes used were FITC, PE, PerCP, APC, PeCy7, AmCyan and 
Pacific Blue. 
 
2.1.8 Mice 
 
All mice used in these studies were maintained on the C57BL/6 (B6) genetic 
background. All animals were housed in single ventilated cages under standard 
conditions. Animal experiments were authorized by the Landesamt für Natur, 
Umwelt und Verbraucherschutz in Nordrhein Westfalen (Recklinghausen, 
Germany) and performed in accordance with the German law for animal 
protection. During survival experiments mice which showed a severe phenotype 
with weight loss (>20% of starting weight), reduced movement, and general 
sickness have been killed at indicated time points assuming time of death. Besides 
the C57BL/6 (B6) mice which were used as wild type (WT) mice different mouse 
strains have been used in these experiments.  
 
DEE mice 
DEE mice are transgenic mice that express ubiquitously the glycoprotein of 
LCMV under the H2k promoter (Hunziker et al., 2003). On the one hand, these mice 
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served as recipients for the generation of bone marrow chimera mice and on the 
other hand, the DEE hearts were used as donors for the heterotopic heart 
transplantation. 
 
IL-10–/–mice  
IL-10 deficient mice lack secretion of the immune modulatory cytokine IL-
10 (Kuhn et al., 1993). As recipient they received a heterotopic transplanted heart. 
 
P14 mice 
P14 T cells recognize the LCMV-GP on MHC class I. The P14 mice express an 
LCMV-GP33-41 specific TCR on CD45.1 positive CD8+ T cells (Pircher et al., 1989) 
and were used for adoptive transfer experiments and as bone marrow donors.  
 
Sv/129 mice 
Sv/129 mice have a different background from C57BL/6 mice. They differ in 
gene loci and are used as two mice strains with different backgrounds for e.g. 
stroke research (Fujii et al., 1997; Gerlai, 1996).  
 
Tcrb–/– mice  
Tcrb–/– mice are genetically engineered immunodeficient mice which lack 
the T cell receptor beta chain (Funabashi et al., 2001). After intravenous injection 
of LCMV-WE, the virus persisted in the mice. Their hearts were used as LCMV 
carrier donor hearts for heterotopic heart transplantation. 
 
2.1.9 Lymphocytic Choriomeningitis Virus (LCMV) 
 
LCMV strain WE originally obtained from F. Lehmann-Grube (Heinrich Pette 
Institute, Hamburg, Germany) was propagated in L929 cells. Mice were infected 
intravenously in the tail vein. Applied concentration was either 200 plaque-
forming units (PFU) or 2x106 PFU. Viral titers were measured in Plaque Assay 
using mouse fibrosarcoma cell line derived from C57BL/6 mice (MC57 cells). 
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2.1.10 Statistical analysis 
  
If not differently stated data are expressed as means and S.E.M. Student’s t-
test was used to detect statistically significant differences between groups. 
Significant differences between several groups were detected by two-way analysis 
of variance (ANOVA).  The level of statistical significance was set at * P < 0.05, ** P< 
0.01 and *** P< 0.001. 
 
2.2 Methods 
 
2.2.1 Bone Marrow Chimera 
 
Creating bone marrow chimera mice is a very useful method to get further 
insights into immunological processes such as influence of donor derived 
hematopoietic stem cells on immune responses. Especially, in the field of 
transplantation medicine, bone marrow chimera experiments play a crucial role 
for tolerance model (Umemura et al., 2001). This model makes it possible to 
distinguish between effects on the immune system in recipient induced by cells 
coming from the donor derived hematopoietic or non-hematopoietic system.  
 
2.2.1.1 Preparation of Donor BM 
 
For the preparation of donor bone marrow, one mouse had to be killed to 
gain bone marrow for transplantation of six mice. Donor and recipients were sex- 
matched. After disinfecting the dead mouse, the abdominal skin was cut open to 
reach the legs till the hip. Femur and tibia got totally removed without breaking 
the bones. Forceps and scissors were necessary to fulfill the procedure. When the 
bones were ready to be flushed, they had to be cleaned in 70% ethanol for three 
minutes and washed with PBS. With help of a 21-gauge needle and medium, the 
bone marrow got flushed after cutting open both sides of each bone. The bone 
marrow (which looked like red, long, thin tissue) had to be collected in a 50 ml 
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tube and vortexed into a single-cell suspension to passage through a strainer.  Re-
suspended in medium, the bone marrow was ready for injection. Around 50 x 106 
bone marrow cells had to be injected intravenously in the tail vein of each mouse 
(Holl, 2013). 
 
2.2.1.2 Recipient Preparation 
 
Six to eight weeks old recipients underwent a full body irradiation by X-ray 
with 9.5 Gy. 24 hours after irradiation, mice received sex-matched bone marrow 
diluted in medium by tail-vein injection. 30 days after bone marrow 
transplantation reconstitution of bone marrow took place in the host.  
 
2.2.2 Heterotopic Heart Transplantation (HTX) 
 
Heart allografts were vascularly anastomosed in an intraabdominal location 
using the technique described previously (Corry et al., 1973; Wu et al., 2006). Graft 
ischemic time was typically 20–25 min and total operative time was 45–50 min 
with a success rate (beating hearts) of more than 90%. Rejection of heart grafts 
was not associated with death of recipients. The graft function was evaluated by 
palpation of the abdominal wall daily after operation. The function of the donor 
heart was assessed using a subjective score of 0 to 3 (zero for no beating; 0.5 for 
very weak beating; one for weak beating; two for moderate beating; three for full 
beating).  
 
2.2.3 Plaque Assay 
 
In this mouse model, virus titers in organs or sera were determined by 
Plaque Assay (Battegay et al., 1991; K. S. Lang, Recher, Navarini, et al., 2005). After 
harvesting and smashing organs in 1ml DMEM supplemented with 5% FCS, each 
cell suspension was transferred in 96-well plates and diluted with DMEM 5%FCS 
so that the cells were titrated at a ratio of 1:3. After transferring the samples in a 
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24- well plate, 200 µl of freshly prepared MC57 cells diluted 8 x 105 cells/ml, were 
added. MC57 cells are susceptible for LCMV infection. Plates were ready for 
incubation and Overlay had to be added between 3 and 5 hours after starting 
incubation at 37°C and 5% CO2. Incubation lasted for two days. At day three, cells 
were stained and evaluated for PFU.  PFU were calculated according to the size of 
the smashed organ; dilution and logarithm of each variable is shown in the graph.  
 
2.2.4 Flow Cytometry 
 
Flow cytometry enables counting of fluorescent marked cells by 4 different 
lasers.  
 
2.2.4.1 Tetramer Staining 
 
Tetramers were provided by the National Institute of Health (NIH) 
Tetramer Facility. In short, 20 μl of blood was stained with allophycocyanin (APC)-
labeled GP33 MHC class I tetramers (GP33/H-2Db) for 15 minutes at 37°C. After 
incubation, the samples were stained with anti-CD8 peridinin-chlorophyll-protein-
complex (PerCP; BD Biosciences, Franklin Lakes, NJ) for 30 minutes at 4°C. 
Erythrocytes were then lysed using 1ml BD lysing solution (BD Biosciences); cells 
were washed once and analyzed by flow cytometry. Absolute numbers of GP33-
specific CD8+ T cells per/μl blood were calculated by FACS analysis using 
fluorescent beads (BD Biosciences). 
 
2.2.4.2 Intracellular Cytokine Staining (ICS) 
 
For intracellular IFN-γ staining, splenocytes and lymphocytes from blood 
were stimulated with GP33 in the presence of Brefeldin A. After 6 hours, cells were 
stained for CD8 (eBioscience) for 30 minutes at 4°C, fixed with 2% Formaldehyde 
for 10 minutes and permeabilized with 1% Triton-X solution, and stained for IFN-γ 
with anti-mouse IFN-γ antibody (eBioscience) and analyzed by flow cytometry. 
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2.2.4.3 CFSE labeled Splenocyte Transfer  
 
To follow proliferation of CD8+ TCR- specific T cells in blood, T cells were 
labeled with carboxyfluorescein succinimidyl ester (CFSE), a molecule, which  
made it possible to track cell proliferation due to decrease of tagged fluorescent 
molecule measured in FITC by flow cytometry. In this study, spleens of P14 mice 
have been smashed, suspended in PBS and filtered through a strainer. One spleen 
was suspended in 10 ml PBS. 5mM of CFSE has been added to the cell suspension 
and an incubation period of 10 minutes at 37°C followed. To eliminate remaining 
CFSE, single cell suspension has been washed twice with 10% FCS in DMEM. After 
discarding the supernatant, labeled cells were resuspended in IMDM to inject 
200µl (106 cells) intravenously in one mouse.  
 
2.2.5 Depletion of CD8+ T Cells 
 
For CD8+ T cell depletion, 500µg/100µl of anti-CD8 antibody clone YTS 
169.4 (Bioxcell) was injected intraperitoneally on day -3 and -1 in bone marrow 
donor mice. 
 
2.2.6 Triggering of Innate Immunity 
 
Innate immune response was triggered by injecting 200µl of 
lipopolysaccharides (LPS) intraperitoneally (250µg/ml) in bone marrow chimera 
mice. 
 
2.2.8 ELISA 
 
Enzyme linked immunosorbent assay (ELISA) has been performed by the 
Mouse IL-10 ELISA Ready-SET-Go!® reagent kit using 20µl of plasma.  
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2.2.9 RT-PCR  
 
Total RNA was isolated from organs with the TriFast®TRIzol (PeqLab, 
Erlangen) isolation method. Tissue samples with a weight range between 50-
100mg have been homogenized in a TissueLyser (QIAGEN, Hilden). RNA was 
reverse-transcribed into cDNA with the QuantiTect Reverse Transcription Kit 
(QiAGEN, Hilden). Gene expression analysis was quantified by RT-PCR using 
SYBR®Green (AppliedBiosystems, Darmstadt) according to the protocol of the 
manufacturer. Expression levels were normalized against GAPDH and compared 
between study groups. 
 
2.2.10 Analysis of Liver and Heart Enzymes 
 
Serum and plasma were analysed in the central laboratory at the university 
hospital Essen for alanine transferase (ALT) and lactate dehydrogenase (LDH) and 
for CK-MB and Trop I. Serum or plasma has been collected from mice at various 
time points. 30µl serum or plasma has been diluted in 270µl PBS and were ready 
for measurement at the central laboratory. 
 
3 Results 
3.1 Transgenic LCMV-GP is ubiquitously expressed  
 
To analyze immune responses of donor derived T cells in recipients 
expressing foreign antigen, DEE mice were used. DEE mice are transgenic mice 
which express LCMV-GP ubiquitously under the H2k promoter. The expression of 
LCMV-GP in the thymus, the organ of central tolerance induction was shown by 
RT-PCR (Figure 3.1A). LCMV-GP is a minor antigen which is presented on MHC 
class I. To confirm that the transgene LCMV-GP is presented by MHC class I 
molecules in host DEE mice, adoptive transfer of GP33 specific CD8+ T cells (P14 T 
cells) was performed.  P14 cells showed proliferation in DEE mice (Figure 3.1B) 
but not in WT mice, when analyzed ex vivo. 
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To emphasize tolerance induction of LCMV-GP specific CD8+ T cells in mice 
carrying the minor antigen LCMV-GP, the F1 generation of P14 mice crossed with 
DEE mice were analyzed for GP33 specific CD8+ T cells. Due to negative selection, 
P14 T cells were deleted centrally (Figure 3.2). 
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Figure 3.1 LCMV-GP expression in DEE mice. A) RT-PCR analysis of LCMV-GP mRNA harvested from 
thymus of WT (n=2), DEE (n=3) and Tcrb deficient (LCMV; n=3) mice which were infected with 2 x 
106 PFU of LCMV-WE representing positive control of LCMV–GP expression due to chronic 
infection at day 10 post-infection. Values show fold change to expression in WT mice. B) 
Proliferation of P14 T cells. Adoptive transfer of CFSE labeled P14 T cells into naïve WT mice and 
DEE mice were assessed by flow cytometry and shown in histogram blot (n=3). 
 
CD8 
Figure 3.2 Presence of GP33 specific CD8+ T cells in thymus and blood. A) Thymus of P14 mice (left 
panel) and P14xDEEmice (right panel) were gated on double positive CD4+/CD8+ T cells and for 
double positive CD90.2/Tet-GP33 T cells in the thymus. CD90.2 is expressed by mouse thymocytes 
and mature T cells. Results are shown as single dot plot. One dot plot is shown as a representative 
of each group (n=2). B) Number of CD8+ T cells in blood was determined in P14, P14xDEE and DEE 
mice shown in white columns and percentage of Tet-GP33 positive CD8+ T cells in black columns 
(n=4), 
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3.2 Host specific CD8+ T cells are not negatively selected after      
BMT 
 
In this murine BMT model, P14 bone marrow was transferred in lethally 
irradiated DEE mice (Figure 3.3). P14 mice revealed LCMV-GP specific CD8+ T 
cells and DEE mice expressed LCMV-GP ubiquitously and present the antigen on 
MHC class I. LCMV-GP was used as a foreign antigen to demonstrate a single minor 
antigen mismatch.  
 
 
 
 
As control, P14 bone marrow was transferred in WT mice. During reconstitution of 
bone marrow in recipients, blood was analyzed weekly for development of P14 T 
cells (Figure 3.4A). The graph shows the kinetic of GP33 specific CD8+ T cells in 
DEE and WT mice recipients after receiving P14 bone marrow. Even though, DEE 
recipients expressed GP33 everywhere in the tissue and present the antigen on 
MHC class I, P14 T cells remained ignorant. The mice did not become ill, indeed, 
measurement of cell damage marker such as LDH and ALT showed a physiological 
amount in sera (Figure 3.4B).  
 
Figure 3.3 Model of BMT. Recipient mice were lethally irradiated (9.5Gy) and received P14 bone marrow 
intravenously. DEE mice expressed GP33 ubiquitously. WT mice recipients were used as control. 
Mice were at least 6-8 weeks old.  
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To characterize ignorant P14 T cells which developed in chimera mice more in 
detail, spleen has been removed after 40 days as reconstitution of bone marrow 
took approximately 30 days. Splenocytes were labeled with CFSE and transferred 
intravenously in different groups of mice. Splenocytes from WT and DEE chimera 
mice were injected i.v. in naïve WT mice, naïve DEE mice and WT mice infected 
with LCMV-WE 6 days post-infection to see whether P14 T cells behave differently 
in an environment of viral peptide presentation or active virus replication. P14 T 
cells which developed either in WT or DEE mice were transferred from spleen to 
WT, DEE or LCMV infected mice, proliferated in response to indigenous GP33-
peptide (DEE) as well as to peptides from replicating virus (LCMV) (Figure 3.5A). 
Ex vivo restimulation of these cells with GP33-peptide to analyze intracellular 
cytokine staining (ICS) revealed no IFN-γ production in the absence of in vivo 
B A                                                         
Figure 3.4 Development of P14 T cells after BMT and measurement of ALT and LDH in sera. A) Number 
of CD8+ T cells in blood was determined weekly in chimera mice by flow cytometry which is shown 
in the upper panel. According to the total number of CD8+ T cells, Tet-GP33 positive CD8+ T cells are 
shown in percentage in the panel below. B) ALT and LDH were determined in sera at indicated days 
post-transplant. Black squares represent mean values of B6 chimera mice at days post-transplant, 
which received P14 bone marrow i.v. (P14 BM-> WT) (n=4). Mean values of T cell number and ALT 
or LDH of irradiated DEE mice receiving P14 bone marrow (P14 BM-> DEE) are shown in white 
squares (n=4). 
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antigen exposure (WT), low IFN-γ production after in vivo GP33-peptide exposure 
and significant IFN-γ production after in vivo exposure to replicating virus.  
In conclusion P14 T cells proliferate in response to GP33-peptide presented 
in DEE mice but they are functionally ignorant. However, if these cells are exposed 
to an environment with actively replicating virus, these cells can be restimulated 
and produce IFN-γ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A                                                         
B                                                         
Figure 3.5 P14 T cells generated in chimera mice got activated ex-vivo. A) 1 x 107 splenocytes of 40-days-
old P14 BM→WT mice and P14 BM→DEE mice were labeled with CFSE and transferred into naïve 
WT mice, DEE mice and WT mice infected i.v. with 2 x 104 PFU of LCMV-WE 1 day after splenocyte 
transfer (n=2-4; pooled from two independent experiments). Proliferation of CD45.1+ CD8+ T cells 
(P14 T cells) derived from spleen was assessed by CFSE dilution 6 days after transfer. Histograms 
show cells gated on CD45.1+ CD8+ T cells in correlation to CFSE. One representative set of data is 
shown. B) Next, these splenocytes were analyzed for IFN-γ production after re-stimulation with the 
LCMV peptide GP33-41 in vitro. An intracellular cytokine staining was performed and CD45.1+ CD8+ 
specific T cells (P14) of either P14 BM→WT or P14 BM→DEE mice were characterized, IFN- 
secreting cells are given as percentage of lymphocytes (n=2-4; pooled from two independent 
experiments). 
 32 3 Results 
  
3.3 Introduction of LCMV-GP minor antigen in hematopoietic stem 
cells leads to deletion of host specific CD8+ T cells after BMT 
 
During minor antigen mismatched BMT, host specific CD8+ T cells were 
present despite of minor antigen expression in the host. The hypothesis was that 
only antigen expressed in the hematopoietic derived cells is able to induce deletion 
of host specific CD8+ T cells in this setting. To test this hypothesis, we mixed P14 
bone marrow cells with DEE bone marrow cells in a 1:1 ratio and transferred them 
into DEE and WT mice. In both groups, host specific CD8+ T cells were deleted 
(Figure 3.6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 P14 T cell kinetic in blood of chimeric mice after mixed bone marrow transplantation. 
Percentage of GP33 specific CD8+ T cells (P14 T cells) was determined in blood by flow cytometry 
at indicted time points after BMT (n=5). 
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3.4 Recipients ignore minor antigen (LCMV-GP) expressed in   
cardiac graft 
 
Heterotopic HTX was performed as murine SOT model. Donor heart was 
harvested from DEE mice and transplanted in WT mice (Figure 3.7).  
 
 
 
 
 
Analyzing host versus graft reaction in SOT-setting showed that GP33 expression 
in the heart was completely ignored. Presence of minor antigen mismatch in 
syngeneic cardiac graft did not induce rejection in a time period of 100 days 
whereas allogenic hearts harvested from Sv/129 mice were rejected in WT mice 
within 10 days (Figure 3.8). Sv/129 mice differ genetically from WT mice by MHC 
(H2 complex) class I and II alleles and the genetic background and were used as 
allograft rejection model (positive control). 
 
Figure 3.7 Model of heterotopic heart transplantation. GP33 expressing heart was harvested from DEE 
mice and transplanted in WT mice.  As control, heart was harvested from WT mice and 
transplanted in WT mice. 
B6 ♡ → B6 
GP33 ♡ → B6 
Sv/129 ♡ → B6 
Figure 3.8 Graft survival curve after HTX. Graft survival was defined as persistence of heart beating. Graft 
survival was independent of survival of recipient mice. B6 (black square), DEE (GP33; white 
square) and Sv/129 (black triangle) hearts were harvested as donor hearts and transplanted in B6 
(WT) mice. Heart beat was determined weekly by abdominal palpation (n=4-5).  
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Figure 3.10 Experiment design. WT mice recipients received either a naïve heart transplant or LCMV loaded 
heart. WT mice receiving a naïve heart transplant were infected with LCMV strain WE 
intravenously.  
Moreover, no development of GP33 specific CD8+ T cells could be detected in WT 
mice recipients transplanted with a syngeneic WT heart or a DEE heart carrying 
the LCMV-GP33 peptide (Figure 3.9). No priming of CD8+ T cells took place. In 
conclusion, minor antigen mismatch was completely ignored by host derived WT 
CD8+ T cells, in this setting. 
 
3.5 Immunological tolerance in an LCMV model 
 
WT mice received either naïve B6 heart or LCMV loaded heart. Effect of viral 
transmitted infection by HTX versus systemic (i.v.) LCMV infection post-
transplantation has been analyzed as followed (Figure 3.10). 
 
  
 
B6 ♡ → B6                      DEE ♡ → B6 
 
Figure 3.9 Tetramer staining of blood after HTX.  At day 100 post-transplant blood from transplanted mice 
receiving either B6 (WT) heart or DEE (GP33) heart were analyzed for GP33 specific CD8+ T cells by 
flow cytometry. Dotplot was gated on lymphocytes. Left panel shows representative dotplot of B6 
(WT) mice receiving B6 (WT) heart (n=3). Right panel shows representative dotplot of B6 (WT) 
mice receiving DEE heart (n=4). 
naïve i.v. 
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3.5.1 LCMV carrier mice 
 
To create LCMV carrier mice, Tcrb-/- mice which cannot mount an antiviral 
immune response because of TCR deficiency required for MHC class I expression, 
have been infected with 2 x 106 PFU of LCMV strain WE. Mice were then 
chronically infected and virus persisted in mice. Virus titer is shown and is 
comparable to LCMV-WE high dose infection (Figure 3.11). LCMV carrier heart 
was used as donor heart which was severely infected with replicating virus. In the 
previous experiments (Figure 3.5) GP33 expression alone was not able to induce 
immune activation. The hypothesis was that only replicating virus was able to 
break immunological ignorance. 
 
 
3.5.2 LCMV transmitted by HTX leads to T cell exhaustion in WT mice 
 
In this setting, viral loaded hearts were transplanted in naïve mice and 
naïve hearts were transplanted in virus infected mice. The syngeneic grafts 
whether naïve or infected were not rejected. The hearts kept on beating and 
recipients survived.  WT mice receiving chronically infected hearts became carrier 
mice; meaning, virus persisted in mice and spread from the transplanted heart to 
other tissue. Mice receiving naïve-HTX and were infected systemically with LCMV 
cleared the virus. Plaque assay of organs and heart transplant showed viral 
Figure 3.11 Virus titers in LCMV donor hearts. Tcrb–/– mice were infected with 2 × 106 PFU of LCMV strain 
WE. Graph shows viral titers in heart after 30 days post-infection (n = 4). Horizontal dotted lines 
designate the detection limit.    
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persistence 30 days post-transplant (Figure 3.12) in LCMV-HTX mice but not in 
LCMV infected naïve-HTX mice. 
 
 
Virus infection could not be controlled in LCMV-HTX mice. Analyzing virus specific 
CD8+ T cells, which normally develop after LCMV-WE infection, revealed a reduced 
GP33 specific CD8+ T cell number in blood (Figure 3.13A). Furthermore viral 
specific response in form of effector cytokine production such as IFN-γ was 
reduced in blood (Figure 3.13B). Together these data demonstrate anti-viral T cell 
exhaustion in chronically infected mice.  T cell exhaustion is defined as a loss of 
effector function (Wherry, 2011; Yi et al., 2010). Gradual loss can be distinguished 
as stages which are determined by diminished or vanished production of effector 
cytokines such as IFN-γ, increased expression of inhibitory receptors and deletion 
of antigen-specific T cells.  In addition, T cell exhaustion correlates with viral 
persistence.  
 
Figure 3.12 Virus titers in organs after LCMV-HTX. Organs have been removed 30 days post-transplant for 
Plaque Assay. White columns show virus titers in spleen, liver, kidney, lung, transplanted heart (Tx) 
and endogenous heart (Endo) removed from WT mice recipients receiving LCMV-loaded hearts 
(n=4). Control group (black columns) received naïve hearts and were infected with LCMV strain 
WE intravenously 15 days post-transplant. 30 days post-infection organs have been harvested for 
Plaque Assay (n=4). Horizontal dotted lines designate the detection limit.    
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3.6 Breaking immunological tolerance  
 
In the study reported here, minor antigen expression in hosts (DEE mice) receiving 
BMT, induced ignorance in donor BM derived minor antigen specific CD8+ T cells 
(P14 cells). Antigen expression in syngeneic graft (DEE heart) during SOT was 
ignored by the lymphoid system of the host (WT mice). Replicating antigen in 
transplant (LCMV- HTX) induced tolerance in naïve transplant recipients due to T 
cell exhaustion. Now the question occurred how to break this tolerance.  
 
 
 
A                                                         B                                                         
Figure 3.13 CD8+ T cell kinetic and IFN-γ production in blood. A) Percentage of GP33 specific CD8+ T cells 
was determined in blood by flow cytometry at indicted time points post-transplant or post-
infection respectively. WT mice received LCMV carrier hearts (white squares; n=4). Control group 
consisted of WT mice which received naïve hearts and were infected i.v. with LCMV strain WE low 
dose 15 days post-transplant (black squares; n=4). Time is shown in days post-transplant and post-
infection respectively.  B) IFN-γ production was assessed by intracellular cytokine staining (ICS) in 
blood gated on CD8+ T cells. White columns represent WT mice receiving LCMV loaded hearts 
(n=4) at days post-transplant and as control, naïve WT mice infected with LCMV strain WE high 
dose at days 8 and 14 post-infection. 
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3.6.1 High frequencies of host specific CD8+ T cells induce limited GvHD after 
stimulation with LPS   
 
Donor derived LCMV-GP minor antigen specific CD8+ T cells (P14) grafted in 
DEE mice remained ignorant, which means, these mice did not develop GvHD. 
However, innate immune activation via Toll-like Receptor (TLR) can have an 
impact on adaptive auto-reactive immune responses (K. S. Lang et al., 2006; K. S. 
Lang, Recher, Junt, et al., 2005).  
Therefore, chimera mice which received P14 bone marrow were treated 
with lipopolysaccharides (LPS). LPS was injected intraperitoneally in P14 BM→WT 
mice and P14 BM→DEE mice 200 days after BMT. Serologically, LDH was 
measured as general marker for cell damage and transaminases as specific 
markers for liver disease. When LPS was administrated LDH was enhanced in P14 
BM→DEE mice but not in P14 BM→WT mice, indicating cell damage took place 
(Figure 3.14). Specific liver enzymes were in normal range. This suggests that LPS 
impacts on immune activation of host specific CD8+ T cells. However, these data 
show that even at high precursor frequencies of minor antigen specific CD8+ T cells 
acute GvHD is not induced.  
 
 
 
 
 
Figure 3.14 ALT and LDH measurement in serum after LPS challenge. P14 bone marrow was transferred 
in DEE and WT mice (white columns P14 BM in DEE mice; black columns P14 BM in WT mice (n=4-
5) pooled from two experiments). 50µg LPS was injected intraperitoneally 200 days after BMT. 1 
and 2 days after LPS challenge, serum was analyzed for ALT and LDH amount.  
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3.6.2 IL-10 deficient mice die after transplantation of LCMV infected hearts 
 
Generation of GP33 specific CD8+ T cells in the presence of DEE 
transplanted heart did not take place due to T cell exhaustion (Figure 3.8). 
Possible mechanisms of CD8+ T cell exhaustion during heart transplantation can 
vary. In this study, CD8+ T cell exhaustion led to tolerance of heart transplant and 
consequently to syngeneic graft survival.  Interleukin-10 is known to play a crucial 
role for CD8+ T cell exhaustion during chronic infection (Blackburn et al., 2007; 
Brooks et al., 2006). Therefore, IL-10 deficient mice were used as recipient (Figure 
3.15).   
 
 
Interleukin-10 is an immunosuppressive cytokine which is secreted by 
various types of cells such as CD8+ and CD4+ T cells, B cells and APCs (Moore et al., 
2001). When mice lack IL-10 during LCMV-HTX, they died (Figure 3.16A). This 
can be due to high numbers of activated CD8+ T cells. Thus, infection with LCMV-
WE intravenously in IL-10 deficient mice led to fast generation of LCMV specific 
CD8+ T cells (data not shown). When LCMV carrier hearts were transplanted into 
IL-10 deficient mice, higher numbers of CD8+ T cells could be detected in blood 
(Figure 3.16B). Indeed, IL-10 was elevated in WT mice receiving an infected heart 
transplant (Figure 3.17A).   Virus titer in blood was not affected by IL-10 loss 
(Figure 3.17B).  
Figure 3.15 Experiment design. LCMV carrier hearts were transplanted in IL-10-/- mice recipients or in WT 
mice recipients. Time line shows the days post-transplant. At indicated time points, blood analysis 
was done by flow cytometry.   
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Figure 3.17 IL-10 and virus titers in plasma and blood after LCMV-HTX. LCMV carrier hearts were 
transplanted in IL-10-/- mice recipients and in WT mice recipients (n=2-4). A) IL-10 was measured 
in plasma by ELISA at day 2 and 6 post-transplant. B) Plaque Assay was performed from blood. 
Virus load was determined by plaque-forming units in blood at days post-transplant. Horizontal 
dotted lines designate the detection limit.    
 
 
 
   
 
 
 
 
IL-10 deficient mice rejected the hearts within 10 days and heart enzymes were 
elevated in IL-10–/– mice (Figure 3.18A). In addition, IL-10–/– mice became ill and 
revealed high levels of LDH and ALT indicating massive cell death in tissue and 
liver damage respectively (Figure 3.18B). The mice revealed a systemic illness 
and died within 10 days due to immunopathology. Together these data show that 
A                                                         B                                                         
Figure 3.16 Survival curve and CD8+ T cell kinetic after LCMV-HTX. LCMV carrier hearts were transplanted 
in IL-10-/- mice recipients (white circle) and in WT mice recipients (black square). A) Mice were 
observed in a time period of 30 days. Survival of mice recipients after LCMV-HTX is shown in 
percentage (n=7-15; pooled from 2 to 3 experiments). B) CD8+ T cells were measured in blood by 
flow cytometry at indicated time points post-transplant (n=2-4). 
A                                                         B                                                         
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IL-10 was essential to prevent syngeneic graft rejection after transplantation of 
viral infected hearts. 
 
 
 
 
 
3.7 Graft rejection by memory T cells 
 
Are memory T cells able to prevent virus persistence? Are they dependent 
on IL-10? Therefore, memory CD8+ T cells were generated in C57BL/6 mice by 
infecting mice with LCMV-WE intravenously. After priming with LCMV, mice 
generated a specific immune response.  In a next step, LCMV carrier hearts were 
transplanted into LCMV infected mice (Figure 3.19).  
Figure 3.18 Analysis of heart and liver enzymes in sera after LCMV-HTX. LCMV carrier hearts were 
transplanted in IL-10-/- mice recipients and in WT mice recipients. A) CK-MB and Trop I (specific 
heart enzymes) were measured in sera at day 4, 6 and 8 post-transplant (n=2-4). B) ALT and LDH 
(marker for liver damage and dell death) were determined in sera at day 4, 6 and 8 post-transplant 
(n=2-4).  
A                                                         B                                                         
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3.7.1 Memory mice recipients reject LCMV infected heart transplant 
 
Transplantation of LCMV infected hearts led to massive CD8+ T cell 
expansion in memory mice (Figure 3.20A). Memory CD8+ T cells got highly 
activated as shown by down regulation of IL-7 receptor (CD127) and CD62L 
(Figure 3.20B). Virus specific memory CD8+ T cells could control LCMV (Figure 
3.21A) and transplanted hearts were early rejected in memory mice (Figure 
3.21B). In line with the acute heart rejection, heart specific parameters, CK-MB 
and Trop I, raised early after transplantation (Figure 3.21C). Histology revealed 
high numbers of infiltrating CD8+ T cells in the heart (data not shown). In 
conclusion, we found that presence of memory CD8+ T cells resulted in fast 
rejection of viral infected hearts, but virus could be controlled and the mice 
survived.  
Figure 3.19 Experiment design. Naïve C57BL/6 (WT) mice were infected at least 20 days before HTX with 
200 PFU of LCMV-WE intravenously and generated memory CD8+ T cells. Memory mice or naïve 
C57BL/6 (WT) mice received LCMV infected hearts and blood analysis were made at indicated time 
points post-transplant. 
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A                                                         B                                                         
Figure 3.20 Characterization of Memory T cells. A) Graph showing frequency of T cells that were positive 
for the MHC class I tetramer of the glycoprotein of LCMV (Tet-GP33+) and for CD8 (CD8+) in blood of 
WT or LCMV infected recipients receiving LCMV loaded hearts shown in days post-transplant (n=3-
5). B) Analysis of activation marker such as CD127, CD62L, CD44 and PD-1 are made by gating TET-
GP33+ CD8+ T cells and shown in a histogram blot at day 6 post-transplant in comparison to day -1 
pre-transplant in blood. One histogram blot is shown as a representative of each group. 
A                                                         B                                                         
C 
Figure 3.21 Virus control and transplant rejection in memory mice. LCMV carrier hearts were 
transplanted in memory mice recipients and in WT mice. A) Virus titers in blood were determined 
by plaque-forming units (PFU) in Plaque assay at days 7 and 16 post-transplant. Horizontal dotted 
lines designate the detection limit (n=4).  B) Allograft survival curve after LCMV-HTX was 
determined by rest of heart beat (n=4-7). Allograft survival was independent of recipient survival. 
C)  Measurement of heart enzymes (CK-MB and Trop I) were determined in sera (n=3-4).  
D 
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4 Discussion 
 
In the study reported here, the role of viral infection in transplantation 
medicine was assessed in a murine LCMV model. Two main experimental but 
clinical relevant conditions have been used: murine bone marrow transplantation 
and heterotopic heart transplantation. Minor antigens as well as viral infection 
influence outcome of patients undergoing BMT or SOT in fully matched donor and 
recipients. The LCMV-GP transgene was used as a peptide in a minor antigen 
mismatch transplantation model. In a next step, the role of replicating antigen was 
analyzed in heterotopic heart transplantation. LCMV transmitted by heart 
transplantation led to T cell exhaustion in WT mice and in consequence to 
syngeneic graft tolerance. Moreover, induction of host antigen (GP33) in 
hematopoietic stem cells led to deletion of host specific CD8+ T cells after BMT. 
 
4.1 Host specific CD8+ T cells proliferate in presence of minor 
antigen in host after BMT 
 
In the murine minor antigen mismatched bone marrow model we 
transplanted P14 bone marrow into DEE mice to analyze the activation of these 
host specific CD8+ T cells. The recipients developed high frequencies of GP33-
specific T-lymphocytes independent of antigen expression in the thymus and 
peripheral organs. Nevertheless, they did not develop lethal disease in form of 
GvHD. To confirm central tolerance induction by recognition of GP33 minor 
antigen and by T cell deletion we crossed P14 mice with DEE mice. Almost no 
GP33-specific CD8+ T cell has been detected in peripheral organs. DEE mice 
express ubiquitously GP33 peptide in organs and transferring CFSE labeled mature 
but naïve P14 T cells into DEE mice led to significant T cell proliferation, suggesting 
that the minor antigen is detectable by the transgenic TCR of the P14 T cells. As 
described in previous publications proliferation of anti-host reactive CD8+ T cells 
could be induced by minor antigen presentation in the host (Mori et al., 2005). It 
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remains unclear, whether presentation of minor antigens in the host can lead to 
ignorance and finally to reduced immunopathology in patients after BMT. 
 
4.2 Triggering the innate immune system can lead to activation of 
host specific CD8+ T cells 
 
We demonstrated that triggering the innate immune system with LPS could 
lead to significant cell damage in DEE recipients whereas WT recipients remained 
unaffected by GP33-specific CD8+ T cells. This is in line with the clinical situation 
where bacterial or viral infection (e.g. CMV) often induces GvHD (Ljungman, 2008). 
Especially for the human cytomegalovirus (HCMV), preexisting data show an 
association of viral infection with increased risk of aGvHD (Boeckh et al., 2004; 
Nichols et al., 2002).  Interestingly, in a clinical trial it was shown that early 
replicative HCMV infection reduces the risk of leukemic relapse in patients with 
acute myeloid lymphoma (AML) (Elmaagacli et al., 2011). Though the underlying 
mechanism is not completely understood yet; a virus-induced abrogation of 
immune ignorance comparable to our murine model and even induction of graft 
versus leukemia (GvL) is a possible explanation for reduced risk of leukemic 
relapse after early replicative HCMV infection. Thus, beyond genetic haplotype 
matches the immune status on bacterial and viral infections of bone marrow 
donors might be helpful for GvHD risk evaluation, which is already performed for 
herpes viruses and HCMV (Pietersma et al., 2011). 
 
4.3 Outlook for possible therapeutic methods in BMT 
 
These data are in contrast to current models, suggesting that low 
frequencies of anti-host reactive CD8+ T cells result in development of GvHD 
(Desmarets et al., 2009; Schroeder et al., 2011). We found that in absence of 
secondary stimulation even high numbers of host-reactive T cells are ignorant. 
GvHD is often associated with GvL. GvL can result in complete control of malignant 
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cells after minor HLA mismatch. Interestingly efficient GvL can occur even in the 
presence of mild GvHD (Klymenko et al., 2011). The reasons for that are not well 
explained. From our data we would suggest that the presentation of leukemic 
antigens in primary lymphoid organs is crucial for the recognition by anti-host 
reactive CD8+ T cells and for early elimination. Therefore, a promising approach to 
treat GvHD would be the inhibition of T cell egress to peripheral organs. This 
would potentially limit aGvHD, but still allow GvL. Such a preparation is 
Fingolimod (FTY720) which is licensed for treatment of relapsing remitting 
multiple sclerosis. Fingolimod prevents the egress of lymphocytes from secondary 
lymphoid organs thereby preventing migration of immune cells to the central 
nervous system (Chun et al., 2010). Fingolimod is not clinically tested in BMT. Even 
though its application seems attractive, Fingolimod has first to be evaluated in 
animal models since it reduces the peripheral lymphocyte count and acts as an 
immunosuppressant. In conclusion we demonstrated that high frequencies of anti-
host reactive CD8+ T cells can remain ignorant after engraftment in recipient and 
do not induce GvHD. 
 
4.4 Immunized recipients have an increased risk for cardiac graft 
rejection 
 
We mimicked the clinical situation of donor-derived viral infection in SOT in 
form of heterotopic heart transplantation in a mouse model. This system allows us 
to focus on recipients’ immune response against virus infection transmitted 
through organ transplantation.  
Clinically, CMV is a major problem in SOT (Razonable et al., 2013). CMV is a 
herpesvirus which is widely spread in human beings. Seroprevalence of CMV 
varies between 30 and 97% in the population (Bate et al., 2010; Cannon et al., 
2010). Consequently, more than 50% of solid organ transplant recipients suffer 
from CMV infection in the first 3 months post-transplant. Seropositivity of donor 
and recipient play a crucial role in morbidity and mortality for the transplant 
recipient. CMV-seropositive donors and recipients are designated as D+ and R+ 
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respectively. According to seroprevalence, different risk groups are categorized. In 
the D+ and R- (D+/ R-) group the recipient has the highest risk for CMV disease. The 
lowest risk for CMV disease is in the case of seronegativity in donor and recipient 
(D-/R-) (Ramanan et al., 2013). A CMV prophylaxis treatment is preserved for 
transplant recipients who are at highest risk for CMV disease (D+/ R-) and (D+/ R+). 
A retrospective study compared morbidity and mortality in four CMV 
donor/recipient serostatus categories (Harvala et al., 2013). As result, the group 
D+/ R+ showed the highest risk for mortality post-transplant, even though CMV 
disease occurs more often in D+/ R- . In line with our data, recipients who have 
been infected once before transplantation (R+) show a strong immune response 
against the allograft (D-) leading to rejection. In our study, LCMV infection via 
transplant (D+) in naïve recipient (R-) mice led to chronic virus infection due to 
CD8+ T cell exhaustion. The grafts survived and showed only partial dysfunction.  
 
4.5 Role of LCMV infection in human beings 
 
Another example for donor-derived infection in humans is LCMV. LCMV is 
an arenavirus, which is very rare in human beings. An infection is usually 
asymptomatic in healthy persons and can be caused after close contact to house 
mice or hamsters (Childs et al., 1992; Childs et al., 1991).  Some cases are known 
where LCMV was transmitted during transplantation. Donor-derived infection in 
several recipients led to death within three weeks after transplantation. The same 
viral strain could be detected in a cluster of patients, where seven of eight 
recipients died. The recipients revealed unspecific symptoms such as diarrhea, 
fever and systemic illness (Fischer et al., 2006). Normally, LCMV infection in non-
immunosuppressed people is asymptomatic.  
Immunosuppression after transplantation aims to reduce immune response 
by the adaptive immune system. Nevertheless, it encloses many side effects such as 
a higher risk of opportunistic infections, a heighten incidence of cancer and toxicity 
(Halloran, 2004).  In our study, viral infected hearts were transplanted in 
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immunocompetent mice and were fully HLA-matched to focus specifically on CD8+ 
immune response. 
 
4.6 T cell exhaustion- a possible mechanism inducing tolerance? 
 
A new perspective for tolerance in SOT is to understand CD8+ T cell 
exhaustion.  Little is known in the field of transplantation medicine. We know that 
T cell exhaustion limits the immune response against chronic infections and 
tumors. In case of recrudescence of exhausted T cells, clearance of infections and 
tumor regression can be induced (Blank et al., 2007).  
Previous clinical studies effort to reactivate exhausted T cells as treatment 
for chronic infections or tumor disease (Sharpe et al., 2015). However, the 
mechanisms leading to T-cell exhaustion are unknown. Further, the role of T-cell 
exhaustion in transplantation or autoimmunity is not defined. Recently, Sarraj et al 
(Sarraj et al., 2014) showed that genetic deletion of selectin ligand for leucocyte 
migration leads to impaired T cell function. They focused on CD4+ T cells and 
induced T cell exhaustion in a murine transplantation model by impaired 
migration capability. They determined T cell exhaustion by impaired effector 
cytokine production (IFN-γ), defective proliferation of CD4+ T cells and higher PD-
1 expression. Knock-out mice recipients providing impaired migration capability 
revealed T cell exhaustion and showed prolonged graft survival. T cells were not 
able to migrate in the MHC II mismatched heart transplant which in consequence 
led to permanent activation of T cells and then to T cell exhaustion. Graft survival 
was significantly increased. The data demonstrate that T cell exhaustion led to 
tolerance of allograft.  
 The fact that IL-10 is an immunoregulatory cytokine that is associated with 
T cell exhaustion, is in line with the above finding (Blackburn et al., 2007). Its 
function during virus infection is described to be immunosuppressive by limiting 
cytokine production and proliferation of CD8+ and CD4+ T cells leading to viral 
persistence. A variety of cells can produce IL-10 such as T cells, B cells and APCs 
(Blackburn et al., 2007; Moore et al., 2001). Clinical studies demonstrated that 
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polymorphisms linked with increased IL-10 production are associated with 
increased susceptibility to chronic HCV infection and increased severity of chronic 
HBV infection (Knapp et al., 2003; Paladino et al., 2006; Persico et al., 2006). Vice 
versa, polymorphisms with reduced expression of IL-10 correlate with a slower 
progression of AIDS in HIV- infected patients (Shin et al., 2000). Its role in 
transplantation medicine is poorly understood. As IL-10 is known for its anti-
inflammatory response and immunosuppressive role, it should abet graft survival. 
Indeed, IL-10 inhibits ischemia/reperfusion injury (Deng et al., 2001), extends 
allograft survival and function (Cypel et al., 2009; Feng et al., 1999; Zuo et al., 
2001) and is essential for the action of regulatory T cells mediating tolerance at 
least in some transplant models (Hara et al., 2001). In our model, IL-10 deficient 
mice receiving LCMV loaded heart died early after transplantation. Loss of IL-10 in 
recipients showed a systemic immune response with immunopathology indicating 
that absence of IL-10 prevents T cell exhaustion. Its immunoregulatory function in 
virus infection through organ transplantation helps tolerating the allograft. 
This changed in case of memorized mice. Memory CD8+ T cells were capable 
to control donor-derived LCMV infection but induced an acute graft rejection. 
Memory T cells play a major role in acute and chronic allograft rejection. Pre-
transplant frequency of donor-specific alloreactive memory T cells in recipient 
correlates with the risk of long-term allograft rejection (Heeger et al., 1999). 
Previous experimental models demonstrate their potential alloreactivity. They 
even showed that cross-reactivity can lead to alloreaction defined as heterologous 
immunity (van den Heuvel et al., 2015). In our case replication competent LCMV in 
heart transplant was rejected in memory mice. These facts emphasize the 
significance of donor-derived viral infection. Immunized patients exposed to viral 
load facing possible alloreaction have to be treated virus specifically (e.g. CMV). It 
decreases significantly graft survival in SOT. IL-10 therapy in case of unexpected 
donor-derived viral infection could be a potential immunotherapy in SOT.  
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5 Summary 
 
Graft versus host disease (GvHD) occurs in 40% of cases with patients having a 
MHC I matched bone marrow transplantation (BMT). Mechanisms causing this 
disease remain to be studied. Here we used a CD8+ T cell transgenic mouse strain 
(P14/CD45.1+) and DEE mice bearing the foreign antigen (LCMV-GP33-41) to 
study mechanisms of tolerance in donor derived host specific CD8+ T cells after 
BMT. We found that host reactive CD8+ T cells were not negatively selected in the 
thymus and developed comparably to host non-specific CD8+ T cells. Host specific 
CD8+ T cells ignored the antigen expressed ubiquitously by host cells but they 
could be activated ex vivo via LCMV-infection. Lipopolysaccharides (LPS) induced 
transient cell damage in DEE mice bearing host specific CD8+ T cells, suggesting 
that induction of host inflammatory response could break this ignorance. In 
conclusion, we found that after BMT host specific CD8+ T cells ignore antigen in 
recipients and that they are only deleted when host antigen is present in the 
hematopoietic system. Moreover, LPS-induced immune activation contributes to 
induction of alloreactivity of host specific CD8+ T cells after BMT. Unexpected 
transmissions of viral pathogens during solid organ transplantation (SOT) can 
result in severe, life-threatening diseases in transplant recipients. Immune 
activation contributes to disease onset; however mechanisms balancing the 
immune response against transmitted virus infection through organ 
transplantation remain unknown. Here, we found, using LCMV, that 
transplantation of LCMV infected hearts led to exhaustion of virus specific CD8+ T 
cells, viral persistence in organs and survival of graft and recipient. Genetic 
depletion of IL-10 resulted in a strong immune activation, graft dysfunction and 
death of mice, suggesting that IL-10 was a major regulator of CD8+ T cell 
exhaustion during SOT. In the presence of memory CD8+ T cells, virus could be 
controlled; however sufficient antiviral immune response resulted in rejection of 
transplanted heart. In conclusion, we found that virus transmitted by SOT cannot 
be controlled by naive recipients due to IL-10 mediated CD8+ T cell exhaustion 
which thereby prevented immunopathology and graft failure whereas memory 
mice recipients were able to control the virus and induced graft failure. 
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7 Abbreviation 
 
Ab antibody 
ALT alanine transferase 
AML acute myeloid lymphoma 
APC antigen presenting cell 
BMT bone marrow transplantation 
CAV cardiac allograft vasculopathy 
CD cluster of differentiation 
CFSE carboxy-flourescein-succinimidyl-ester  
CK-MB creatinine kinase of type muscle brain 
CMV cytomegalovirus 
DMEM dulbecco`s modified eagle medium 
DNA deoxyribonucleic acid 
ELISA enzyme linked immunosorbent assay 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FITC fluorescein‐isothiocyanate 
GvHD graft versus host disease 
GvL graft versus leukemia 
GP glycoprotein 
Gy gray 
HBV hepatitis B virus 
HCV hepatitis C virus 
HLA human leukocyte antigen 
 61 7 Abbreviation 
HTX heart transplantation 
i.p. intraperitoneal   
i.v. intravenous  
IVC  inferior vena cava 
IL interleukin 
IMDM iscoves modified dulbeccos medium 
IFN-γ interferon gamma 
LCMV lymphocytic choriomeningitis virus 
LDH lactate dehydrogenase 
LPS lipopolysaccharide 
MC57 mouse fibrosarcoma cell line 
NAT nucleic acid testing 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PE  phycoerythrin 
PeCy7 phycoerythrin‐cyanin‐7 
PerCP  peridin‐chlorophyll 
PFU plaque forming units 
PSG  penicilin‐streptomycin‐glutamine 
qRT‐PCR  quantitative real time PCR 
RIC reduced intensity conditioning 
SOT solid organ transplantation 
TCR t cell receptor 
TLR  toll‐like receptor 
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Trop I troponine I 
WT wild type 
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